Jordi Sarto, Diana Esteller-Gauxax, Adrià Tort-Merino, Núria Guillén, Agnès Pérez-Millan, Neus Falgàs, Sergi Borrego-Écija, Guadalupe Fernández-Villullas, Beatriz Bosch, Jordi Juncà-Parella, Anna Antonell, Laura Naranjo, Raquel Ruiz-García, Josep María Augé, Raquel Sánchez-Valle, Albert Lladó, Mircea Balasa
Plasma biomarkers have emerged as promising tools for identifying amyloid beta (Aβ) pathology. Before implementation in routine clinical practice, confounding factors modifying their concentration beyond neurodegenerative diseases should be identified. We studied the association of a comprehensive list of demographics, comorbidities, medication and laboratory parameters with plasma p-tau181, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) on a prospective memory clinic cohort and studied their impact on diagnostic accuracy for discriminating CSF/amyloid PET-defined Aβ status...
December 27, 2023: Journal of Neurology